This month several new drugs were (re)introduced on the Canadian market:
- ARGATROBAN – is an anticoagulant that is a small molecule direct thrombin inhibitor.
- WINREVAIR (sotatercept) – is a medication used for the treatment of pulmonary arterial hypertension.
- DAYBUE (trofinetide) – is a medication used for the treatment of Rett syndrome.
Several drugs changed their therapeutic class:
- TABRECTA (capmatinib) – is an anticancer medication used for the treatment of metastatic non-small cell lung cancer whose tumors have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR.
- TEPMETKO (tepotinib) – is an anti-cancer medication used for the treatment of adults with non-small cell lung cancer (NSCLC).
- VYVGART (efgartigimod alfa) – is a medication used to treat myasthenia gravis.
And the following drug was discontinued:
- caplacizumab (Cablivi)